Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the united states, 1998-2009

Psychiatric Services

Volumn 63, Issue 1, 2012, Pages 83-86

  Pillarella, Jessica ^a   Higashi, Ashley ^c   Alexander, G Caleb ^b,c   Conti, Rena ^b,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; MOOD STABILIZER; OLANZAPINE; RISPERIDONE;

ARTICLE; BIPOLAR DISORDER; DRUG APPROVAL; DRUG USE; FOOD AND DRUG ADMINISTRATION; MONOTHERAPY; PRESCRIPTION; UNITED STATES;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DRUG APPROVAL; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; HUMANS; MODELS, STATISTICAL; PHYSICIAN'S PRACTICE PATTERNS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84857848572     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201100092     Document Type: Article

References (16)

1. Sikich L, Frazier JA, McClellan J, et al: Double-blind comparison of first- and second- generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the Treatment of Early- Onset Schizophrenia Spectrum Disorders (TEOSS) Study. American Journal of Psychiatry 165:1420-1431, 2008
2. Jones PB, Barnes TRE, Davies L, et al: Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 63: 1079-1087, 2006 (Pubitemid 44498387)
3. Alexander GC, Gallagher SA, Mascola A, et al: Increasing off-label use of antipsychotic medicines, 1995-2008. Pharmacoepidemiology and Drug Safety 20:177-184, 2011
4. Rosenheck RA, Leslie DL, Doshi JA: Second-generation antipsychotics: cost-effectiveness, policy options, and political decision making. Psychiatric Services 59:515-520, 2008
5. Drugs@FDA. Available at www.accessdata. fda.gov/scripts/cder/drugsatfda. Accessed Jun 15, 2010
6. Berndt ER, Bui L, Reiley D, et al: The Roles of Marketing, Product Quality, and Price Competition in the Growth and Composition of the US Anti-Ulcer Drug Industry. NBER working paper 4904.
7. Cambridge, Mass, National Bureau of Economic Research, 1994. Available at www.nber.org/papers
8. International Classification of Diseases, 9th Revision, Clinical Modification. Los Angeles, PMIC, 1995
9. Dorsey E, Rabbani A, Gallagher SA, et al: Impact of FDA black box advisory on antipsychotic medication use. Archives of Internal Medicine 170:96-103, 2010
10. Higashi AS, Zhu S, Stafford RS, et al: National trends in ambulatory asthma treatment, 1997-2009. Journal of General Internal Medicine 26:1465-1470, 2011
11. Stafford RS, Radley DC: The underutilization of cardiac medications of proven benefit, 1990 to 2002. Journal of the American College of Cardiology 41:56-61, 2003 (Pubitemid 36044404)
12. Hardin JW, Hilbe JM: Generalized Estimating Equations. Boca Raton, Fla, Chapman and Hall, 2003
13. Van Winkel R, De Hert M, Van Eyck D, et al: Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disorders 10: 342-348, 2008 (Pubitemid 351637699)
14. Furberg CD, Herrington DM, Psaty BM: Are drugs within a class interchangeable? Lancet 354:1202-1204, 1999 (Pubitemid 29460460)
15. Wazana A: Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 283:373-380, 2000
16. Calabrese JR, Keck PE, Macfadden W, et al: A randomized, double-blind, placebocontrolled trial of quetiapine in the treatment of bipolar I or II depression. American Journal of Psychiatry 162:1351-1360, 2005 (Pubitemid 40905587)